Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dollar General Corp. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Dollar General Corp. trades at $120.2 (market cap $26.49B). The key difference: Alnylam Pharmaceuticals, Inc. and Dollar General Corp. are close in size by market cap, and Dollar General Corp. pays a 1.97% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DG | |
|---|---|---|
Market Cap | $29.60B | $26.49B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $156.26 |
52-Week Low | $205.48 | $95.94 |
Enterprise Value | $27.56B | $40.93B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Dollar General (DG) trades at $119.65, down 2.24% amid broader market weakness. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, trading below analyst consensus target of $128.45. Recent earnings beats and positive cash flow trends ($395M net in 2025) support the bullish case, though profit margins have compressed from 7.01% in 2022 to 2.77% in 2025. Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages.
Outlook remains positive given 52% analyst buy ratings and projected earnings growth, but investors face margin pressure and competitive threats from Walmart and Amazon. The stock offers value characteristics with upside to price targets, though same-store sales growth and cost management will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
